Tirzepatide

Tirzepatide is a synthetic 39-amino-acid peptide developed by Eli Lilly and approved as a once-weekly subcutaneous injection. It is sold under two brand names for two different indications: Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Both contain the same active molecule.

What makes tirzepatide distinctive is that it is the first approved dual agonist targeting two incretin hormone receptors at once: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Earlier medications in this therapeutic space, such as semaglutide, act on the GLP-1 receptor alone. By engaging both pathways, tirzepatide is sometimes described as a "twincretin."

Structurally, tirzepatide is based on the native GIP sequence and includes a C20 fatty-diacid chain that binds to albumin, extending its half-life to roughly five days and enabling once-weekly dosing. To understand the broader class of incretin-based therapies, see our overview of GLP-1 receptor agonists.

Tirzepatide is now one of the most widely discussed metabolic peptides. For foundational concepts, our explainer on what peptides are provides useful context.

Incretins are gut hormones released after eating that help regulate blood sugar and appetite. Tirzepatide mimics the actions of two of them simultaneously.

Through the GLP-1 receptor, tirzepatide:

• Stimulates glucose-dependent insulin secretion from pancreatic beta cells
• Suppresses glucagon release when glucose is elevated
• Slows gastric emptying, prolonging the feeling of fullness
• Acts on appetite centers in the hypothalamus to reduce food intake

Through the GIP receptor, tirzepatide is thought to enhance insulin secretion further and may improve how fat tissue handles lipids and insulin sensitivity. The combined activation of both receptors appears to produce greater effects on blood glucose and body weight than targeting GLP-1 alone, though the precise contribution of GIP signaling in humans remains an active area of research.

Because insulin secretion is glucose-dependent, tirzepatide carries a relatively low intrinsic risk of hypoglycemia when used on its own, though that risk rises when it is combined with insulin or sulfonylureas. The net clinical result is improved glycemic control alongside substantial appetite suppression and weight loss. This information is educational and not a substitute for professional medical guidance.

The SURMOUNT program is the series of phase 3 clinical trials that evaluated tirzepatide for weight management in people with obesity or overweight.

In SURMOUNT-1, published in the New England Journal of Medicine in 2022, more than 2,500 adults with obesity but without diabetes received tirzepatide or placebo for 72 weeks. Average weight reductions were striking:

At the highest dose, more than half of participants lost at least 20% of their body weight — magnitudes of weight loss with a medication that had previously been associated mainly with bariatric surgery.

Subsequent trials extended these findings: SURMOUNT-2 studied participants with type 2 diabetes, SURMOUNT-3 examined weight loss after an intensive lifestyle intervention, and SURMOUNT-4 looked at weight maintenance after withdrawal, showing that stopping treatment led to substantial regain. Across the program, the average weight loss of roughly 20-22% at the top dose is among the highest reported for an anti-obesity pharmacotherapy to date. These results are why tirzepatide dominates weight-loss peptide search traffic.

How Effective Is It for Type 2 Diabetes?

Before its obesity indication, tirzepatide was first studied for type 2 diabetes in the SURPASS trial program. These studies measured changes in HbA1c (a marker of average blood glucose over roughly three months) as the primary endpoint.

Across the SURPASS trials, tirzepatide produced large reductions in HbA1c — frequently in the range of 2.0 to 2.5 percentage points at higher doses — alongside meaningful weight loss. In head-to-head comparisons, it generally outperformed comparators including injectable semaglutide, insulin degludec, and insulin glargine on both glucose control and weight.

A notable proportion of participants achieved HbA1c levels below 5.7%, a value typically considered within the normal (non-diabetic) range, though achieving a laboratory target is not the same as curing the underlying condition. The dual mechanism is widely credited for this combination of robust glycemic improvement and weight reduction, which is unusual among glucose-lowering agents.

Tirzepatide's commercial success reflects this clinical performance: Mounjaro and Zepbound together generated approximately $10.1 billion in revenue in the third quarter of 2025 (about $6.5 billion and $3.6 billion respectively). Treatment decisions for diabetes must be individualized by a healthcare professional and are outside the scope of this educational guide.

How Does Tirzepatide Compare to Semaglutide?

The most common comparison is between tirzepatide and semaglutide (marketed as Ozempic for diabetes and Wegovy for weight loss), the leading single-agonist GLP-1 medication.

In the head-to-head SURPASS-2 diabetes trial, tirzepatide produced greater reductions in HbA1c and body weight than semaglutide 1 mg. More recently, dedicated head-to-head obesity research has reinforced that tirzepatide tends to deliver greater average weight loss. The addition of GIP receptor activity is the most cited explanation for this difference.

That said, the "better" choice depends on the individual: tolerability, cost, insurance coverage, availability, and specific health conditions all matter. Both medications share a similar gastrointestinal side-effect profile and the same thyroid-tumor boxed warning. A clinician is best placed to weigh these factors for a given person.

What Is the Regulatory and Legal Status?

Tirzepatide is a fully approved prescription medication, which distinguishes it sharply from many research peptides that are sold "for research use only."

Its regulatory milestones include:

• 2022: FDA approval as Mounjaro for type 2 diabetes
• 2023: FDA approval as Zepbound for chronic weight management
• Approvals in additional jurisdictions, including the European Union, have followed

Because it is FDA-approved, tirzepatide should be obtained only through legitimate prescription channels and a licensed pharmacy. During periods of high demand and supply shortages, compounded versions and gray-market "research" products have circulated; these may carry significant risks regarding purity, dosing accuracy, and sterility, and their legal status is contested. Quality and authenticity cannot be assumed outside regulated supply chains.

Legal and regulatory status varies by country and can change over time. To learn how this molecule fits within the wider landscape of metabolic peptides, see our guide to GLP-1 receptor agonists and our overview of leading peptides. This article is for educational purposes only, is not medical advice, and you should consult a healthcare professional before considering any treatment.

The most common adverse effects of tirzepatide are gastrointestinal and tend to be most pronounced during dose escalation:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Reduced appetite and abdominal discomfort

These effects are usually mild to moderate and often diminish over time, which is precisely why the titration schedule is so gradual. Beyond common side effects, several more serious considerations apply:

• Thyroid C-cell tumors: tirzepatide carries a boxed warning because related compounds caused thyroid tumors in rodents; it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2.
• Pancreatitis: cases have been reported, and the drug should be discontinued if pancreatitis is suspected.
• Gallbladder disease: rapid weight loss can increase the risk of gallstones.
• Hypoglycemia: risk increases when combined with insulin or sulfonylureas.
• Kidney injury: dehydration from severe vomiting or diarrhea can affect kidney function.

Tirzepatide is not recommended during pregnancy. As with the broader peptide category, individual responses vary, and a personalized risk assessment is essential. For general background on this topic, see our medical disclaimer. This list is not exhaustive; discuss all risks and your medical history with a qualified clinician.

Tirzepatide is sold by Eli Lilly under two brand names that contain the same molecule. The approved uses differ by region.

Sleep apnea. The FDA approval rests on the two SURMOUNT-OSA trials (NEJM, 2024). At 52 weeks, the apnea-hypopnea index fell by 25.3 and 29.3 events per hour with tirzepatide versus about 5 events per hour with placebo. In the EU, the sleep apnea results are described in the trial section of the Mounjaro label (section 5.1) but are not a separate indication.

Head-to-head with semaglutide. In SURMOUNT-5 (NEJM, 2025), 751 adults with obesity and without diabetes were randomized to tirzepatide or semaglutide for 72 weeks. Mean weight change was -20.2% with tirzepatide and -13.7% with semaglutide (P<0.001), and waist circumference fell by 18.4 cm versus 13.0 cm. Gastrointestinal events were the most common adverse events in both groups.

Heart failure. In SUMMIT (NEJM, 2025), 731 patients with heart failure with preserved ejection fraction (HFpEF) and obesity were followed for a median of 104 weeks. Cardiovascular death or a worsening heart failure event occurred in 9.9% with tirzepatide versus 15.3% with placebo (hazard ratio 0.62). Lilly nevertheless withdrew its US application for this indication in May 2025, after the FDA asked for an additional confirmatory trial. The EMA closed its own assessment in January 2026 without a separate HFpEF indication; the SUMMIT results are described in the EU label instead.

From 2022 to 2024, tirzepatide injections were on the FDA drug shortage list, which allowed pharmacies to compound copies. The FDA declared the shortage resolved in October 2024 and confirmed that decision on 19 December 2024. The grace periods for state-licensed 503A pharmacies and for 503B outsourcing facilities then ended in early 2025.

On 30 April 2026, the FDA proposed not to include tirzepatide, semaglutide and liraglutide on the 503B Bulks List (Federal Register notice of 1 May 2026). The agency tentatively concluded that the nominations did not show a clinical need for outsourcing facilities to compound these drugs from bulk active ingredient, and it states that cost, convenience and backorders are not part of that analysis. The comment period was extended in June 2026. As of early November 2026, no final decision had been published in the Federal Register. The notice concerns the 503B pathway only.

The US HHS enforcement-discretion policy of 28 October 2026 concerns six other peptides (BPC-157, TB-500, MOTS-c, Epitalon, Semax and KPV) and does not cover tirzepatide. Compounded tirzepatide is not FDA-approved: it has not been reviewed for safety, effectiveness or quality, and the FDA has warned about adverse events and administration errors reported with compounded GLP-1 products.

The tirzepatide trial program is one of the largest in metabolic medicine, but several questions remain open.

• Effect after stopping: the main obesity trials lasted 72 to 88 weeks, and SURMOUNT-4 showed substantial weight regain after withdrawal. There is no evidence that the weight loss persists once treatment stops.
• Hard outcomes in obesity: lower weight, blood pressure and glucose do not by themselves prove fewer heart attacks, strokes or deaths. In SUMMIT, the benefit came from heart failure events, and cardiovascular deaths were few (8 versus 5).
• Muscle and bone: part of the weight lost is lean mass. Whether this affects strength, falls or fractures in older adults is not settled.
• Comparisons with other drugs: apart from SURPASS-2 and SURMOUNT-5, comparisons with semaglutide or newer molecules come from separate trials and cannot be read as head-to-head results.
• Thyroid signal: the C-cell tumors seen in rodents have been neither confirmed nor excluded in humans, so the boxed warning remains.
• Unregulated products: none of these data apply to tirzepatide sold as a "research peptide", whose identity, purity and sterility are not verified.

This section is educational and is not medical advice.